Brief: Nevro Announces FDA Approval Of HFX IQ Spinal Cord Stimulation System To Personalize Treatment Of Chronic Pain
12/10/2022 23:32
Oct 12 (Reuters) - Nevro Corp NVRO.N :
* NEVRO ANNOUNCES FDA APPROVAL OF HFX IQ™ SPINAL CORD
STIMULATION
SYSTEM TO PERSONALIZE THE TREATMENT OF CHRONIC PAIN
* NEVRO CORP - WILL INITIATE A LIMITED RELEASE OF SENZA HFX
IQ IN
U.S. THIS QUARTER, WITH A BROAD U.S. MARKET LAUNCH PLANNED FOR
EARLY 2023
Source text for Eikon: ID:nPn3JRrlha
Further company coverage: NVRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nevro
See all newsNevro Corp reports results for the quarter ended December 31 - Earnings Summary
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro